Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NYXH Stock Summary
Top 10 Correlated ETFs
NYXH
In the News
Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates
Nyxoah SA (NYXH) came out with a quarterly loss of $0.41 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.52 per share a year ago.
Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024
Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024 Mont-Saint-Guibert, Belgium – February 15, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and financial year 2023 on Tuesday, March 5, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.
Why Is Nyxoah (NYXH) Stock Up 4% Today?
Nyxoah (NASDAQ: NYXH ) stock is rising higher on Monday as the company prepares to participate in the Piper Sandler 35th Annual Healthcare Conference this week. That conference is set to take place from Tuesday through Thursday in New York.
Nyxoah S.A. (NYXH) Q3 2023 Earnings Call Transcript
Nyxoah S.A. (NASDAQ:NYXH ) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Mikaela Kirkwood - Corporate Communications & Investor Relations Manager Olivier Taelman - Chief Executive Officer Loic Moreau - Chief Financial Officer Conference Call Participants Joe Federico - Stifel Simran Kaur - Piper Sandler Ed White - H.C.
Nyxoah to Release Third Quarter 2023 Financial Results on November 8, 2023
Nyxoah to Release Third Quarter 2023 Financial Results on November 8, 2023 Mont-Saint-Guibert, Belgium – October 26, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter of 2023 on Wednesday, November 8, 2023, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.
Nyxoah to Participate in the Cantor Fitzgerald Global Healthcare Conference
Nyxoah to Participate in the Cantor Fit z gerald Global Healthcare Conference
Nyxoah to Participate in Upcoming Investor Conferences
Nyxoah to Participate in Upcoming Investor Conferences Mont-Saint-Guibert, Belgium – September 5 , 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in two upcoming investor conferences in New York City. Olivier Taelman, Nyxoah's Chief Executive Officer, will deliver corporate updates at the H.C.
Nyxoah S.A. (NYXH) Q2 2023 Earnings Call Transcript
Nyxoah S.A. (NASDAQ:NYXH ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Mikaela Kirkwood - Corporate Communications & Investor Relations Manager Olivier Taelman - Chief Executive Officer Loic Moreau - Chief Financial Officer Conference Call Participants Joe Federico - Stifel Ed White - H.C.
Nyxoah SA (NYXH) Reports Q2 Loss, Tops Revenue Estimates
Nyxoah SA (NYXH) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.21 per share a year ago.
Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023
Nyxoah to Release Second Quarter 2023 Financial Results on August 8 , 202 3
NYXH Financial details
NYXH Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.04 | 0.12 | 0 | |
Net income per share | -0.35 | -0.68 | -1.16 | -1.21 | 0 | |
Operating cash flow per share | -0.29 | -0.39 | -1.06 | -1.11 | 0 | |
Free cash flow per share | -0.56 | -0.98 | -1.56 | -1.75 | 0 | |
Cash per share | 0.28 | 5.1 | 5.69 | 3.67 | 0 | |
Book value per share | 0.18 | 5.37 | 6.24 | 4.66 | 0 | |
Tangible book value per share | -0.1 | 4.49 | 5.18 | 3.11 | 0 | |
Share holders equity per share | 0.18 | 5.37 | 6.24 | 4.66 | 0 | |
Interest debt per share | 0.41 | 0.65 | 0.58 | 0.63 | 0 | |
Market cap | 445.55M | 355.3M | 483.55M | 120.89M | 0 | |
Enterprise value | 448.3M | 274.54M | 359.71M | 114.88M | -8.91M | |
P/E ratio | -61.41 | -29.02 | -17.51 | -3.87 | 0 | |
Price to sales ratio | 0 | 5.15K | 567.54 | 39.2 | 0 | |
POCF ratio | -74.69 | -50.65 | -19.09 | -4.2 | 0 | |
PFCF ratio | -37.92 | -20.08 | -13.02 | -2.68 | 0 | |
P/B Ratio | 120 | 3.66 | 3.25 | 1 | 0 | |
PTB ratio | 120 | 3.66 | 3.25 | 1 | 0 | |
EV to sales | 0 | 3.98K | 422.2 | 37.25 | -2.05 | |
Enterprise value over EBITDA | -67.41 | -24.14 | -15.94 | -4.46 | -2.07 | |
EV to operating cash flow | -75.15 | -39.14 | -14.2 | -4 | 0 | |
EV to free cash flow | -38.15 | -15.52 | -9.68 | -2.55 | 0 | |
Earnings yield | -0.02 | -0.03 | -0.06 | -0.26 | 0 | |
Free cash flow yield | -0.03 | -0.05 | -0.08 | -0.37 | 0 | |
Debt to equity | 2.32 | 0.12 | 0.08 | 0.1 | 0.1 | |
Debt to assets | 0.57 | 0.1 | 0.07 | 0.08 | 0.08 | |
Net debt to EBITDA | -0.41 | 7.1 | 5.49 | 0.23 | -2.07 | |
Current ratio | 2.23 | 14.7 | 12.1 | 6.72 | 4.73 | |
Interest coverage | -130.32 | -56.69 | -12.67 | -7.52 | -12.24 | |
Income quality | 0.83 | 0.58 | 1.03 | 0.96 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 164.42 | 13.04 | 5.82 | 0 | |
Research and developement to revenue | 0 | 42.17 | 6.99 | 5.14 | 6.13 | |
Intangibles to total assets | 0.38 | 0.14 | 0.15 | 0.27 | 0 | |
Capex to operating cash flow | 0.97 | 1.52 | 0.47 | 0.57 | 0 | |
Capex to revenue | 0 | -154.78 | -13.87 | -5.3 | 0 | |
Capex to depreciation | -13.36 | -17.23 | -7.11 | -8.46 | 0 | |
Stock based compensation to revenue | 0 | 36.94 | 1.49 | 0.87 | 0 | |
Graham number | 1.18 | 9.04 | 12.76 | 11.25 | 0 | |
ROIC | -0.49 | -0.1 | -0.18 | -0.25 | -0.4 | |
Return on tangible assets | -0.77 | -0.12 | -0.19 | -0.29 | -0.35 | |
Graham Net | -0.19 | 4.24 | 4.85 | 2.78 | 0 | |
Working capital | 4.4M | 87.71M | 128.49M | 85.35M | 53.91M | |
Tangible asset value | -2.02M | 81.34M | 123.3M | 80.35M | 98.02M | |
Net current asset value | -3.51M | 77.22M | 117.85M | 74.51M | 42.22M | |
Invested capital | 2.32 | 0.12 | 0.08 | 0.1 | 0.1 | |
Average receivables | 1.42M | 1.88M | 2.08M | 2.88M | 4.6M | |
Average payables | 890K | 994.5K | 2.41M | 4.49M | 5.57M | |
Average inventory | -366K | 27.5K | 200.5K | 614K | 2.1M | |
Days sales outstanding | 0 | 8.7K | 1.08K | 383.23 | 501.16 | |
Days payables outstanding | 989.63 | 9.92K | 4.81K | 1.58K | 1.36K | |
Days of inventory on hand | 0 | 669.17 | 416.8 | 279.94 | 730.66 | |
Receivables turnover | 0 | 0.04 | 0.34 | 0.95 | 0.73 | |
Payables turnover | 0.37 | 0.04 | 0.08 | 0.23 | 0.27 | |
Inventory turnover | 0 | 0.55 | 0.88 | 1.3 | 0.5 | |
ROE | -1.95 | -0.13 | -0.19 | -0.26 | -0.44 | |
Capex per share | -0.28 | -0.59 | -0.5 | -0.63 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.05 | 0.02 | 0.04 | 0.03 | 0 | |
Net income per share | -0.51 | -0.46 | -0.45 | -0.27 | 0 | |
Operating cash flow per share | -0.4 | -0.41 | -0.41 | -0.37 | 0 | |
Free cash flow per share | -0.56 | -0.53 | -0.5 | -0.49 | 0 | |
Cash per share | 3.67 | 3.71 | 2.95 | 2.53 | 0 | |
Book value per share | 4.66 | 4.83 | 4.04 | 3.79 | 0 | |
Tangible book value per share | 3.11 | 3.19 | 2.48 | 2.19 | 0 | |
Share holders equity per share | 4.66 | 4.83 | 4.04 | 3.79 | 0 | |
Interest debt per share | 0.64 | 0.5 | 0.45 | 0.45 | 0 | |
Market cap | 120.89M | 193.31M | 210.85M | 192.83M | 0 | |
Enterprise value | 114.88M | 172.24M | 206.98M | 192.53M | -8.91M | |
P/E ratio | -2.27 | -4.06 | -4.12 | -6.33 | 0 | |
Price to sales ratio | 92.49 | 438.34 | 190.47 | 197.57 | 0 | |
POCF ratio | -11.66 | -18.12 | -17.85 | -18.15 | 0 | |
PFCF ratio | -8.36 | -14 | -14.7 | -13.6 | 0 | |
P/B Ratio | 1 | 1.55 | 1.82 | 1.78 | 0 | |
PTB ratio | 1 | 1.55 | 1.82 | 1.78 | 0 | |
EV to sales | 87.9 | 390.57 | 186.97 | 197.27 | -4.88 | |
Enterprise value over EBITDA | -14.55 | -16.52 | -18.82 | -19.53 | 0.8 | |
EV to operating cash flow | -11.08 | -16.15 | -17.53 | -18.13 | 0 | |
EV to free cash flow | -7.95 | -12.48 | -14.43 | -13.58 | 0 | |
Earnings yield | -0.11 | -0.06 | -0.06 | -0.04 | 0 | |
Free cash flow yield | -0.12 | -0.07 | -0.07 | -0.07 | 0 | |
Debt to equity | 0.1 | 0.1 | 0.11 | 0.12 | 0.1 | |
Debt to assets | 0.08 | 0.08 | 0.09 | 0.1 | 0.08 | |
Net debt to EBITDA | 0.76 | 2.02 | 0.35 | 0.03 | 0.8 | |
Current ratio | 6.72 | 7.11 | 5.99 | 5.55 | 4.73 | |
Interest coverage | -1.96 | -37.36 | -237.66 | -169.02 | -11.53 | |
Income quality | 0.83 | 0.91 | 1 | 1.08 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.88 | 12.04 | 5.37 | 4.92 | 0 | |
Research and developement to revenue | 3.5 | 13.96 | 5.97 | 6.73 | 4.01 | |
Intangibles to total assets | 0.27 | 0.28 | 0.31 | 0.34 | 0 | |
Capex to operating cash flow | 0.39 | 0.29 | 0.21 | 0.33 | 0 | |
Capex to revenue | -3.13 | -7.11 | -2.29 | -3.64 | 0 | |
Capex to depreciation | -8.3 | -5.65 | -4.51 | -6.85 | 0 | |
Stock based compensation to revenue | 0.43 | 2.29 | 0.68 | 0.54 | 0 | |
Graham number | 7.34 | 7.07 | 6.38 | 4.76 | 0 | |
ROIC | -0.07 | -0.08 | -0.1 | -0.07 | -0.1 | |
Return on tangible assets | -0.13 | -0.11 | -0.13 | -0.09 | -0.09 | |
Graham Net | 2.78 | 2.82 | 2.14 | 1.76 | 0 | |
Working capital | 85.35M | 87.56M | 76.09M | 65.78M | 53.91M | |
Tangible asset value | 80.35M | 82.58M | 71.09M | 62.82M | 98.02M | |
Net current asset value | 74.51M | 75.97M | 64.49M | 54.18M | 42.22M | |
Invested capital | 0.1 | 0.1 | 0.11 | 0.12 | 0.1 | |
Average receivables | 3.01M | 3.08M | 3.5M | 4.22M | 5.16M | |
Average payables | 3.83M | 3.22M | 2.06M | 2.4M | 4.15M | |
Average inventory | 738K | 1.07M | 1.2M | 1.43M | 2.51M | |
Days sales outstanding | 222.97 | 595.51 | 331.87 | 401.59 | 294.57 | |
Days payables outstanding | 964.84 | 748.29 | 571.15 | 575.36 | 763.02 | |
Days of inventory on hand | 170.71 | 642.34 | 246.16 | 457.77 | 410.95 | |
Receivables turnover | 0.4 | 0.15 | 0.27 | 0.22 | 0.31 | |
Payables turnover | 0.09 | 0.12 | 0.16 | 0.16 | 0.12 | |
Inventory turnover | 0.53 | 0.14 | 0.37 | 0.2 | 0.22 | |
ROE | -0.11 | -0.1 | -0.11 | -0.07 | -0.11 | |
Capex per share | -0.16 | -0.12 | -0.09 | -0.12 | 0 |
NYXH Frequently Asked Questions
What is Nyxoah S.A. stock symbol ?
Nyxoah S.A. is a BE stock and trading under the symbol NYXH
Is Nyxoah S.A. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $30. The lowest prediction is $30 and the highest is $30
What is NYXH stock prediction ?
What is Nyxoah S.A. stock quote today ?
Nyxoah S.A. stock price is $18.8 today.
Is Nyxoah S.A. stock public?
Yes, Nyxoah S.A. is a publicly traded company.